Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 232

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 232
---
 is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. A copy of the registration statement and the exhibits filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov.

We maintain a corporate website at www.tuhurabio.com. Information contained in, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations.

<div align='center'>151</div>

INDEX TO FINANCIALSTATEMENTS TUHURA (F/K/A KINTARA THERAPEUTICS, INC.) FINANCIAL STATEMENTS

| Report of Independent Registered Public Accounting Firm                                                                                  
 Consolidated Balance Sheets as of June 30, 2024 and 2023                                                                                 
 Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023                                                         |     | F-3  
 F-5  
 F-6  |
|:-----------------------------------------------------------------------------------------------------------------------------------------|:----|:-----|
| Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended June 30, 2024 and 2023                                     |     | F-7  |
| Consolidated Statements of Cash Flows for the Years Ended June 30, 2024 and 2023                                                         |     | F-8  |
| Notes to the Consolidated Financial Statements                                                                                           |     | F-9  |
| Condensed Consolidated Interim Balance Sheets as of September 30, 2024 and June 30, 2024                                                 |     | F-31 |
| Condensed Consolidated Interim Statements of Operations (Unaudited) for the three months ended September 30, 2024 and 202